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Abstract
Background: Vaccines have profoundly impacted global health although concerns persist about their potential
role in autoimmune or other adverse reactions. To address these concerns, vaccine components like immunogens
and adjuvants require critical evaluation not only in healthy subjects but also in those genetically averse to vaccine
constituents. Evaluation in autoimmune-prone animal models of adjuvants is therefore important in vaccine
development. The objective here was to assess the effectiveness of experimental adjuvants: two phytol-derived
immunostimulants PHIS-01 (phytanol) and PHIS-03 (phytanyl mannose), and a new commercial adjuvant from
porcine small intestinal submucosa (SIS-H), relative to a standard adjuvant alum. Phytol derivatives are hydrophobic,
oil-in water diterpenoids, while alum is hydrophilic, and SIS is essentially a biodegradable and collagenous protein
cocktail derived from extracellular matrices.
Results: We studied phthalate -specific and cross-reactive anti-DNA antibody responses, and parameters associated
with the onset of autoimmune disorders. We determined antibody isotype and cytokine/chemokine milieu induced
by the above experimental adjuvants relative to alum. Our results indicated that the phytol-derived adjuvant PHIS-
01 exceeded alum in enhancing anti-phthalate antibody without much cross reactivity with ds-DNA. Relatively, SIS
and PHIS-03 proved less robust, but they were also less inflammatory. Interestingly, these adjuvants facilitated
isotype switching of anti-hapten, but not of anti-DNA response. The current study reaffirms our earlier reports on
adjuvanticity of phytol compounds and SIS-H in non autoimmune-prone BALB/c and C57BL/6 mice. These
adjuvants are as effective as alum also in autoimmune-prone NZB/WF1 mice, and they have little deleterious
effects.
Conclusion: Although all adjuvants tested impacted cytokine/chemokine milieu in favor of Th1/Th2 balance, the
phytol compounds fared better in reducing the onset of autoimmune syndromes. However, SIS is least
inflammatory among the adjuvants evaluated.
Background
Prophylactic vaccination is considered the most cost-
effective way to control diseases; however, in recent
years, there has been growing doubts about the benefits
of vaccines, primarily because of largely unsupported
claims that constituents in vaccine formulations may
have long-lasting deleterious effects. These concerns
have led to a surge of efforts to redesign vaccines by
employment of modern technologies involving recombi-
nant protein antigens, purified allergens, and pathogen-
associated offending agents [1]. Alongside, there are new
efforts directed to molecularly defined adjuvants or
immunostimulants that nonspecifically boost immuno-
genic potentials of a vaccine. Once considered “immu-
nologists’ dirty tricks”, adjuvants are garnering
considerable attention with regard to their modes of
action, safety, and effectiveness. A major focus is to
overcome the constraints of empiricism in the choice of
adjuvants and develop efficacious vaccines for popula-
tions with varying degrees of immune competence.
To develop safe and broadly effective immunostimu-
lants from structurally diverse compounds, ranging from
bacterial products and inorganic salts to biosynthetic * Correspondence: sghosh@indstate.edu
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In an effort to address the issue, we focused on the phy-
tol component of chlorophyll and studied different phy-
tol derivatives for adjuvanticity [3,4]. Although phytol, a
diterpenoid related to vitamin E, is known for many
beneficial effects in animal studies, it could also be toxic
as an adjuvant at high doses [5,6]. In earlier studies, we
observed that modified phytol compounds such as
PHIS-01 (Phytanol) and PHIS-03 (Phytanyl mannose)
are safe and highly effective adjuvants in immunocom-
petent inbred strains of mice, BALB/c and C57BL/6
[3,4,7,8]. They enhance immunogenicity of many soluble
protein antigens and also of heat-killed pathogens
[3,4,7,8]. In some instances, phytol compounds work
better than alum, the widely us e da d j u v a n tl i c e n s e df o r
human usage. Arguably, not all vaccine recipients are
equally immunocompetent. This necessitates an evalua-
tion of putative adjuvants alone and in combination
with vaccine materials in both normal and compromised
subjects.
This study focused on autoimmune-susceptible NZB/
W F1mice strains that develop renal pathology, circulat-
ing immune complexes and auto-antibodies like anti-ds-
DNA antibodies. In these mice, immune complexes get
deposited in the glomerulus and incite strong immuno-
logical and inflammatory responses characterized by
production of pro-inflammatory cytokines and chemo-
kines, recruitment and activation of circulating leuko-
cytes, and tissue damage. Despite being immune
enhancers, adjuvants could also cause aggravation of
autoimmune disorders. An isoprenoid adjuvant, pristane,
has been shown to promote lupus-like syndromes and
pathologic nephritis in both autoimmune-prone and
non-susceptible mouse strains after a single intra-perito-
neal administration [9-11]. This is in contrast to the
effects of isoprenoids phytol and its derivative PHIS-01
[3]. Furthermore, squalene, a triterpene and Freunds’
adjuvants (CFA/IFA) could also provoke lupus-like syn-
dromes in non autoimmune- prone BALB/c mice [12].
Obviously these adjuvants in a vaccine would likely be
harmful in genetically predisposed or environmentally
compromised individuals. In this context, not only phy-
tol, but also its derivatives like PHIS-01 have been
found safer [3]. Whether this is true for PHIS-03 (phyta-
nyl mannose), which by virtue of its composition is less
hydrophobic than PHIS-01, is not known.
Another experimental adjuvant, SIS (porcine small
intestinal submucosa) is a collagenous extracellular
matrix (ECM) preparation from Cook biotech, that is
licensed for use in human and utilized widely as a non-
toxic scaffolding biomaterial in wound healing [13-17].
In many studies, including ours, SIS proved to be a
highly effective adjuvant in immunocompetent mice
strains [18]. Since SIS contains evolutionarily conserved
proteins such as collagen and traces of other proteins of
ECM, it can be regarded as a cocktail of adjuvants.
However, how effective it is in autoimmune prone mice
NZB/WF1 has not been previously addressed.
In an earlier report, we established that phthalate,
which is a plasticizer often used in medical devices and
as a solvent in cosmetics, can induce cross reactive anti-
dsDNA antibody response in both non autoimmune
prone mice (BALB/c) as well susceptible NZB/WF1
mice [19-21]. However, only NZB/WF1 mice develop
aggravated lupus-like syndromes characterized by high
levels of antibodies, renal pathology and considerable
mortality rates [19-21]. In this report, we used phtha-
late-KLH conjugate as the immunogen in NZB/WF1
mice with or without alum or the experimental adju-
vants SIS, PHIS-01 and PHIS-03. This study was under-
taken to examine immune-modulatory changes inflicted
by choice of adjuvant, which may either suppress or
aggravate the autoimmune syndromes in NZB/WF1
initiated by phthalate. We specifically addressed whether
all these adjuvants (1) induce phthalate-cross reactive
anti-DNA response; (2) exacerbate these adverse effects
following booster immunizations; and (3) affect host
immune microenvironment in terms of systemic chemo-
kines and cytokines.
Methods
Animals and Antigen
Female NZB/WF1 mice 8 weeks of age were purchased
from Jackson laboratory and were housed in the animal
facility of Indiana State University under a protocol
approved by the Institutional Animal Care and Use
Committee (IACUC) of Indiana State University. Ortho-
phthalate-protein conjugates were prepared by azo-cou-
pling of diazotized 4-aminophthalic acid (disodium) to
KLH as described by Ghosh et al [22].
Immunization Regimen
The phytol derivatives, PHIS-01 and PHIS-03 (US
patent pending), were obtained by chemical modification
of phytol according to the literature [23-26]. Suspen-
sions of porcine small intestinal submucosa (SIS hydrate,
SIS-H), a commercial biomaterial for surgical use were
provided by Cook Biotech, Lafayette, IN. Alum was pur-
chased from Sigma Chemical. The inocula consisted of
200 μL of phthalate-KLH (100 μg/mice) and equal
volumes of either PHIS-01 (43 mg), PHIS-03 (5 mg),
SIS-H (5 mg in 15% arlacel A, an emulsifier), or Alum.
Doses were chosen based on our previous studies in
BALB/c and C57BL/6 [8]. These ingredients were vigor-
o u s l ym i x e daf e wt i m e si nas y r i n g ea n db yv o r t e x i n g .
Inocula thus prepared were administered intra-peritone-
ally (i.p.) to six to eight-week old NZB/WF1 mice in a
volume of 400 μL. Mice were given two booster
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immunization through retro-orbital veins. The parallel
control groups of mice were immunized with only
ortho-phthalate-KLH but no adjuvant. To determine
how long the effects of immunizations would persist,
the adjuvanted and control groups were administered
with just phthalate-KLH, 5 months after the last immu-
nization. Five days after this immunization, mice were
bled, sera collected and assayed for antibody response.
Assessment of Serum Levels and Isotype of Anti-
Phthalate and Anti-DNA Antibodies
Serum anti-phthalate and anti-DNA antibody responses
were determined in triplicates using enzyme linked
immunosorbant assays (ELISA), as described previously
[19]. Isotyping was done in triplicates using mice sera at
1/1000 dilution using ELISA plates coated with either
phthalate-BSA or calf thymus DNA. Commercial iso-
type-specific rabbit antisera at 1:500 dilutions were used,
and the assay was carried according to the manufac-
turer’s protocol (Southern Biotech, Birmingham, AL).
Assessment of Cytokine and Chemokines
Cytokine and chemokine profiles of control and experi-
mental mice were assessed using mouse RayBiotech
inflammatory cytokine array kits. Sera collected were
diluted 1:5 in the reagent provided with the kits. Detection
of cytokine was done according to the manufacturer’sp r o -
tocol. Membranes were exposed to X-ray films (Kodak X-
OMAT AR film), and signal intensities were quantified
and analyzed using Image J software from NCBI [27]. Bio-
tin- positive and negative controls at six spots were used
to normalize the results from different membranes. For
each spot, the net optical density level was determined by
subtraction of background density from the sample density
and divided by the density of positive controls. The results
were expressed as a percentage of relative intensity (RI) of
experimental to positive control.
Renal Pathologic Evaluation
At 8 months of age, mice were sacrificed, and urine and
blood samples were collected. Blood urea nitrogen
(BUN) and proteinuria were tested using Azostix and
Multistix [19]. Proteinuria and BUN were estimated fol-
lowing the manufacturers’ protocols. Kidneys tissues iso-
lated were fixed in 4% paraformaldehyde. Slides were
stained using hemat o x y l i na n de o s i n( H & E ) .H i s t o l o g y
was performed double-blindly at the laboratory of Dr.
Roland M. Kohr M.D., Chief of Pathology and Certified
Pathologist at the Terre Haute Regional Hospital.
Statistical evaluation
One-way ANOVA was used to determine statistical sig-
nificance compared to no-adjuvant treated group. Levels
of p ≤ 0.05 were considered statistically significant. Data
were expressed as mean ± SD.
Results
Effects of adjuvants on antibody response to phthalate in
NZB/WF1 mice
Anti-phthalate antibody responses were induced in NZB/
W F1 mice (8 weeks old) by repeated vaccination and
sera assayed for evaluation of adjuvants. Groups of mice
(n = 5) received two booster immunizations at 10- day
intervals and then again after 5 months (by then the mice
were 8 months old) of resting, and were injected with
only phthalate-KLH but no adjuvant. Alongside, the con-
trol groups were exposed to phthalate-KLH without adju-
vant. Results shown in Figure 1 (A, B) reveal that all mice
immunized with adjuvanted phthalate-KLH developed
significant levels of high-titer antibodies. However, the
phytol derivative PHIS-01 enhanced antibody titer 10-
fold over what was registered with SIS-H, PHIS-03, and
alum. Moreover, only the adjuvanted groups, but not the
control non-adjuvanted groups, responded with high-
levels of serum anti-phthalate antibody following anti-
genic stimulation given after a period of five months.
Among the adjuvanted groups, PHIS-01-treated group
was the best responder in terms of specific antibody
response, followed by alum. Responses in PHIS-03 and
SIS-H groups were relatively less robust.
Immunization with phthalate-KLH has previously been
shown to evoke cross-reactive antibody to self- ds-DNA
[19]. We determined whether adjuvants could influence
induction of this cross-reactivity that was previously
reported to occur when mice were injected with phthalate-
KLH and Diethyl hexyl phthalate (DEHP) [3]. The results
in Figure 1 (C, D) show that mice immunized with alum-
adsorbed phthalate-KLH developed significantly higher
levels of anti-DNA response compared to phytol or SIS
adjuvants after two booster immunizations (p ≤ 0.05).
When all groups were rechallenged with phthalate-KLH
after a 5-month period, they experienced an upswing in
anti-DNA response that varied considerably among adju-
vant-treated groups. The order of response in terms of titer
was higher in alum and SIS-H groups, followed by PHIS-01
treated group. Mice immunized with phthalate-KLH emul-
sified in PHIS-03 developed less anti-DNA response.
Effects of Adjuvants on antibody isotype profile
The quality of antibody response to both phthalate and
ds-DNA in adjuvant-treated groups was further assessed
in terms of isotype switching after repeated immuniza-
tions. The results in Figure 2 (A, B) compared the effec-
tiveness of each adjuvant to modulate Ig isotypes
induced following immunization with phthalate. How-
ever, in the adjuvanted groups, there was a clear indica-
tion of isotype switching, the most discernible one being
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conjugate could only induce a modest level of IgG sub-
classes. All groups significantly induced major IgG sub-
classes with the following trend in magnitude IgG1>
IgG2b ≥ IgG2a ≥ IgG3. The relative ratios of (IgG2a+
IgG 2b+ IgG3)/IgG1 induced in response to alum and
experimental adjuvants indicate that the specific antibo-
dies elicited using alum, SIS-H and PHIS-03 are largely
IgG1; this is suggestive of a Th2 bias (Figure 2A). Inter-
estingly, PHIS-01was unlike the other adjuvant-treated
groups and developed significantly high IgG2a and
IgG2b levels directed to phthalate (Figure 2A). While
the isotype profile of anti-phthalate response was
marked by an increase in IgG subclass, the anti-DNA
response induced consisted mostly of IgM class with
only low levels of IgG subclasses (Figure 2B).
Changes in chemokine microenvironment due to
adjuvants
Chemokines are considered important regulators of
innate immunity. It is very likely that adjuvant efficacy
lies in their ability to induce chemotactic factors and
pro-inflammatory cytokines, which regulate the interplay
and cross-talk between innate and acquired immune
systems. As shown in Figure 3 and analyzed in Figure 4,
treatments with phthalate KLH alone or in combination
with different adjuvants resulted in induction of clusters
of chemotactic factors, which are known to be responsi-
ble for recruitment of cells belonging to innate immu-
nity, namely, neutrophils, monocytes, macrophages and
B1 cells. Analyses of Figure 4A show that LIX and MIP-
g (high expression,) MCP-1, lymphotactin, SDF-1,
MCSF, Eotaxin, Eotaxin 2, KC, I-TAC, and MIG (med-
ium expression ) were induced by antigen alone and
also in combination with either ALUM, or phytol deri-
vatives PHIS-01 and PHIS-03. The SIS-treated group
also expressed the same cytokines but less pronounced.
Interestingly, PHIS-01 induced more BLC, G-CSF and
FAS ligand. Later after 5 months, when all adjuvanted
and control mice groups received phthalate KLH alone,
the chemokine profiles (Figure 4B) differed among
groups in magnitude. Mice receiving only phthalate-
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Figure 1 Antibody response in autoimmune-prone NZB/WF1. Mice immunized with phthalate-KLH Conjugate induce both anti-phthalate
Antibody and anti-DNA Responses. The results represent sera of at least 5 mice tested individually using ELISA. A) anti-phthalate antibody levels
after 2
nd booster immunization. B) Anti-DNA antibody levels after 2
nd booster immunization. C) anti-phthalate antibody levels after 3
rd booster
immunization with antigen alone. D) Anti-DNA antibody levels after 3
rd booster immunization with antigen alone. The results represent mean
from individual sera ± SD (n = 5 mice per group). The significance in experimental groups was determined relative to the group given antigen
only (no adjuvant group) at the level of p ≤ 0.05.
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seem to be constitutive in NZB/WF1 mice. Whereas
PHIS-01, PHIS-03, and SIS-H down- regulated the
expression of MIG and TIMP-1, alum augmented
expressions of I-TAC, G-CSF, Eotaxin, MIG, lymphotac-
tin and MCP-1 (Figure 4). Interestingly, mice receiving
SIS-H upregulated the expression of BLC, suggesting an
increase in involvement of B1 cells.
Changes in cytokine microenvironment due to adjuvants
Immunogenic stimulation changes local cytokine milieu
that in turn helps to recruit specific T helper and differ-
ent effector cells. Cytokines IFN-g, IL-2, IL-12, and G-
CSF promotes T-helper-mediated reactions and stimu-
lates strong cellular immune responses, while IL-3, -4,
-5, -6, -10, and IL-13 brings out Th2 response favoring
specific humoral response. The hallmark of lupus could
be due to an imbalance between Th1 and Th2-related
cytokines [28]. In order to assess the cytokine profile
induced in immunized mice, we collected sera after 2nd
booster immunizations from all experimental and non-
adjuvanted control groups. We also assessed sera from
mice given a 3
rd booster immunization with phthalate-
KLH alone.
Results of this study are given in Figure 3 and ana-
lyzed in Figure 5. As shown in Figure 5A, NZB/W F1
mice immunized with phthalate KLH alone or with
adjuvants as well registered moderate expressions of
cytokines that modulate both Th1 (due to IFN-g, IL-12)
and Th2 (due to IL-3, -4, -10, and -13) populations, and
a low but detectable levels of pro-inflammatory cyto-
kines associated with inflammatory response (IL-1, IL-6,
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Figure 2 Determination of IgG Sub-classes. Determination of IgG sub-classes of (A) anti-phthalate antibodies and (B) anti-DNA induced with
phthalate-KLH conjugates mixed in different adjuvants. The results represent sera of at least 5 mice tested individually using ELISA using
commercial ELISA isotyping kits. The results represent mean from individual sera ± SD (n = 5 mice per group). The significance in experimental
groups was determined relative to the group given antigen only (no adjuvant group) at the level of p ≤ 0.05
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Page 5 of 12IL-17, TNF-a). Alum and PHIS-01 produced an upward
trend in IL-1b, IL-17, IL-6, and IL-10, while PHIS-03
induced more of IL-12 P70. All adjuvant-treated groups
induced high levels of anti-inflammatory cytokines
TNFR II, TNFR I, and TIMP1; also induced a high level
of IL-4 compared to INF-g which may suggest Th2
dominance. Expression of cytokines described above was
less pronounced in groups treated with SIS-H.
Interestingly, five months after the 2
nd booster immuni-
zation, NZB/WF1 mice that received only phthalate KLH
had significantly lower expressions of cytokines tested
than those in adjuvanted groups. Clearly, adjuvants in
Figure 3 Systemic cytokine and chemokine profiles in NZB/WF1 mice immunized with phthalate-KLH.N Z B / W F 1m i c e( N=5 )w e r e
immunized as described under Materials and Methods, and sera (collected after 2
nd booster, and then the 3
rd booster with the antigen
phthalate-KLH alone) were diluted 1:5 and subjected to cytokine and chemokine antibody arrays. Each cytokine was measured in duplicate spots
and displayed in the array template as shown. The image shown in (A) represents serum cytokine and chemokine profiles of mice treated with
different adjuvants in combination with antigen after receiving two booster immunizations, and the image shown in (B) represents serum
cytokine and chemokine profiles of mice treated with different adjuvants in combination with the antigen following the 3
rd booster
immunization with antigen alone.
Aachoui and Ghosh BMC Immunology 2011, 12:61
http://www.biomedcentral.com/1471-2172/12/61
Page 6 of 12vaccine formulations made a difference. Adjuvants magni-
fied antibody response and conferred longer memory of
this response brought about with changes in chemokine/
cytokine microenvironment. During the 32-week post-
immunization period, PHIS-03 induced increased expres-
sions of IL-1b, INF-g, IL-3, IL-17 and TNFa to levels simi-
lar to those induced by PHIS-01 or alum. However, there
was no significant change noticed on the level of these
cytokine in mice treated with SIS-H. It is noteworthy that
PHIS-03 caused down-regulation of TNFR I, TNFR II, and
IL-12 P40P70, whereas SIS-H, alum and PHIS-01 did not.
All adjuvant-treated groups, however, down regulated the
expression of TIMP-1.
Signs of Nephritis
Repeated immunizations of NZB/WF1 mice with phtha-
late-KLH plus different adjuvants resulted in signifi-
cantly higher anti-phthalate response but the anti-DNA
response varied among adjuvant-treated groups. In
order to determine whether any clinical signs of nephri-
tis were evident following development of phthalate-
induced anti-DNA antibody, we determined urinary pro-
tein and blood urea nitrogen (BUN) levels in all NZB/
WF1 groups at 8 months of age. Results in Table 1
revealed that mice treated with phthalate-KLH plus
alum or SIS-H had higher levels of anti-DNA antibodies
than in PHIS-01, or PHIS-03. On examination of kidney
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Figure 4 Systemic chemokine profiles in NZB/W F1 mice immunized with phthalate-KLH. NZB/W F1 mice (N = 5) were immunized as
described under Materials and Methods, and sera collected (after 2
nd booster, and then the 3
rd booster with the antigen phthalate-KLH alone)
were diluted 1:5 and subjected to cytokine and chemokine antibody arrays. Each cytokine was measured in duplicate spots and displayed in the
array template as shown. Densities of each spot from images shown in Figure 3 were semi-quantified using image J software [27] and expressed
as relative units to positive controls provided with the array. The image in (A) represents chemokine profiles in sera of mice immunized 3 times
with the antigen and adjuvants, and the image shown in (B) represents chemokine profiles of mice treated receiving a 3
rd booster immunization
with antigen alone.
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Page 7 of 12tissues for histopathological changes in a double blind
fashion, no major changes were noted in connective or
glomerular tissues between untreated or adjuvant-trea-
ted groups (Figures 6 and 7). We primarily detected dif-
ferent levels of lymphoid infiltration. Groups treated
with alum, PHIS-01, PHIS-03, and SIS-H had medium
lymphoid aggregates.
These results suggest that while treatments with
phthalate-KLH in combination with adjuvants increased
anti-DNA levels, no severe signs of nephritis or
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Figure 5 Systemic cytokines profiles of NZB/W F1 mice immunized with phthalate-KLH. NZB/W F1 mice (N = 5) were immunized as
described in materials and methods, and sera collected after 2
nd, and 3
rd booster immunizations were diluted 1:5 and subjected to cytokine and
chemokine antibody arrays. Each cytokine is represented by duplicate spots in the array as shown in the array template. Densities of each spot
from images shown in figure 3 were semi-quantified using image J software and expressed as relative units to positive controls provided in the
array. The image in (A) represents cytokine profiles in sera of mice immunized 3 times with the antigen and adjuvants, and the image shown in
(B) represents cytokine profiles of mice treated receiving a 3
rd booster immunization with antigen alone.
Table 1 Assessment of clinical parameters of kidney pathology
NZB/W F1 immunized with Phthalate- KLH in combination with different adjuvants
Untreated mice No adjuvant ALUM PHIS-01 PHIS-03 SIS-H
Proteinura (mg/dL) 0.3 126 166.7 132 47.5 232
BUN (mg/dL) 15 39.6 53.33 46.5 23.25 56.5
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Figure 6 Renal histopathology. Kidney tissues from following six groups of NZB/W F1 mice previously described were harvested at 8 months
of age and examined as described in materials and methods. Representative H&E stained kidneys (magnification ×100 ) are shown as: Group A:
age matched mice; Group B: Mice immunized with phthalate-KLH alone; Group C: Mice immunized with phthalate-KLH adsorbed to alum; Group
D: Mice immunized with phthalate-KLH emulsified with PHIS-01; Group E: Mice immunized with phthalate-KLH emulsified with PHIS-03; Group F:
Mice immunized with phthalate-KLH emulsified with SIS-H.
A  A  B  C 
D  E  F 
Figure 7 Renal histopathology. Kidney tissues from following six groups of NZB/W F1 mice previously described were harvested at 8 months
of age and examined as described in materials and methods. Representative H&E stained kidneys (magnificationx400) are shown as: Group A:
age matched mice; Group B: Mice immunized with phthalate-KLH alone; Group C: Mice immunized with phthalate-KLH adsorbed to alum; Group
D: Mice immunized with phthalate-KLH emulsified with PHIS-01; Group E: Mice immunized with phthalate-KLH emulsified with PHIS-03; Group F:
Mice immunized with phthalate-KLH emulsified with SIS-H.
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more, mice did not die prematurely in all adjuvant-trea-
ted groups except in alum-treated group, where 2 out 5
mice treated died at 8 months of age, and only 1 mouse
out of 5 died in untreated mice as well as in those trea-
ted with SIS-H or PHIS-01. However, there was no mor-
tality in mice treated only with phthalate-KLH alone or
in combination with PHIS-03. The average life span of
female NZB/WF1 mice is 245 days.
Discussion
During this study, we hypothesized that appropriate
adjuvants can alter host microenvironment, specifically
the cytokine milieu; this may bestow ameliorating effects
by changing the course of immune response. Previously,
we showed that phthalate as a conjugate or as DEHP
(diethyl hexyl phthalate, a plasticizer) can induce cross
reactive anti-DNA antibody response, and promote
lupus-like syndromes in NZB/WF1 mice [19-21]. The
ability of phthalate to induce both anti-phthalate and
cross reactive anti-DNA antibodies was, therefore, uti-
lized to assess the efficacy and safety of novel adjuvants,
PHIS-01, PHIS-03, and SIS-H relative to alum. We used
alum as a reference adjuvant since it is the only human-
licensed adjuvant and in many respects similar to
experimental adjuvants tested in this study. Anti-phtha-
late IgG subclasses induced as a result of these adju-
v a n t ss u g g e s t sab i a st o w a r d st h eT h 2r e s p o n s e .S u c ha
response typically is helpful primarily to combat extra-
cellular bacteria, but it may be beneficial against intra-
cellular bacteria like Francisella tularensis (33).
However, the role of antibodies in protection is better
documented against extracellular than intracellular
pathogens.
Phytol-based adjuvants and SIS biomaterials seem to
be as effective as alum in enhancing anti-phthalate anti-
body response. However, their impacts differed with
respect to inducement of cross reactive anti-ds-DNA
response with the ageing of the mice. In 3 months old
NZB/W F1 mice, the response to phthalate culminates
in high-titer anti-phthalate antibodies in all adjuvanted
groups. Relatively, PHIS-03 treated group registered the
lowest anti-ds-DNA response. Overall, anti-DNA
response in all cases is of low titer, low-affinity IgM
type antibody which is not linked to pathogenicity or
aggravation of lupus-like diseases [29-31]. In contrast,
high affinity IgG2a and IgG3 anti-DNA antibody classes
are considered pathogenic, because they aggravate
lupus-like diseases [31,32]. Furthermore, there are
reports demonstrating that when IgM autoantibodies
are induced, they reduce the severity of autoimmune
pathology due to IgG autoantibodies [31]. We have
observed that as the NZB/WF1 mice grow older, by the
eighth month their serum levels of Ig2a and other IgG
isotypes are higher in antigen and alum-treated groups
compared to those treated with only the experimental
phytol-based adjuvants. Previous reports by Lim et al.
also showed that inclusion of CFA/IFA in vaccine for-
mulations containing phthalate KLH increases IgG2a
anti-DNA antibody, which correlates with lupus-like
symptoms in treated NZB/WF1mice [21]. The results
suggest that, our experimental adjuvants are superior to
the alum group.
The above assessment is also supported by cytokine/
chemokine. Cytokines and chemokines play an essential
role in the outcome of immune response [33]. The pro-
files of chemokines, proinflammatory cytokines, and
Th1/Th2 ratios assessed in this study clearly establish
that PHIS and SIS compounds have ameliorating effects
as adjuvants. Both alum and new adjuvants are capable
of inducing chemokines such as LIX, BLC, MCP-1,
RANTES, and Eotaxin. These chemokines are necessary
for the recruitment of neutrophils, monocytes, macro-
phages and immature dendritic cells (iDC), as well as B
cells; all these cells play important roles in uptake of
antigen and subsequent development of adaptive
response [34]. However, over-expression of chemokines
such as MCP-1, RANTES, or BLC has been linked to
lupus nephritis in patients and in animal models of the
disease [35-39]. But at 8 months of age and despite
repeated exposure to phthalate, all adjuvanted groups
promote only moderate levels of these chemokines.
Overall, only limited pro-inflammatory response has
been observed in all groups. The pro-inflammatory
response in terms of IL-1a,I L - 1 b,I L - 6a n dT N F - a due
to PHIS-01 and PHIS-03 is similar to that of alum. The
SIS-H biomaterial is even better; they provoke no mea-
surable pro-inflammatory cytokines. Interestingly, all
adjuvants can cause moderate lymphocyte infiltration as
shown in kidney histology.
Infiltration of neutrophils and monocytes to kidney is
known to correlate with proteinuria and onset of kidney
damage [40,41]. There is virtually no onset of renal
pathology in mice that are 8-month old. This is unlike
what has been reported about Freunds’ adjuvants and
squalene in MF59 [12,19,42,43]. Possibly the explanation
lies in IL-10, which actually goes up and hinders pro-
inflammatory forces. Alum and PHIS-01 cause marked
increase in IL-10 expression balancing the effect caused
by pro-inflammatory cytokines. However, this is not the
only reason for the outcome of immune response to
phthalate triggered by each adjuvant.
Another hallmark of lupus is the imbalance of Th1/
Th2 cytokines [28]. In a previous study, it has been
shown that hydrocarbon oil adjuvant like pristane can
induce an overproduction of Th1 polarizing cytokines
like INF-g [28]. This, together with high levels of IL-6
and TNF-a, can aggravate lupus-like diseases in rodents
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Page 10 of 12[42]. In our study, alum, PHIS-01 and PHIS-03 can
induce more Th1 and Th2 cytokines than SIS-H. In
addition, PHIS-01 is very effective in inducing IL-12,
and this is the only cytokine that can facilitate produc-
tion of significant amount of IgG2a subclass signifying a
shift towards Th1. Interestingly, the Th1 and Th2
responses generated by different adjuvants is directed
more toward phthalate as is evident by induction of IgG
subclass, whereas the cross reactive anti-ds DNA
response is mostly IgM with little IgG subclass switch-
ing. This ability of adjuvants to selectively activate anti-
gen-specific T cells without provoking auto-reactive
class-switching T cells is of great interest in adjuvant
d e s i g n .I ti sw o r t h w h i l et oa s s e s sa l s ot h ee f f i c a c yo f
adjuvants at the level of antibody gene repertoire, espe-
cially at the level of the antibody light chain repertoire.
As previously documented in several reports, induction
of specific light chain-like V kappa1 genes greatly
increases the pathogenic properties of autoantibodies
produced during autoimmune response [44,45]. Our
ongoing study would focus on characterization of anti-
body light chain repertoire induced by different adju-
vants and its significance on suppression or aggravation
of phthalate induced lupus like autoimmune response.
Conclusion
In conclusion, alum, SIS-H, or phytol compounds do
not engender lupus-like syndromes in NZB/WF1 mice.
They appear to be safe and highly effective. No deleter-
ious effects of physiological significance result from the
use of experimental adjuvants described here. In this
regard, these adjuvants are superior to other oil-in-water
adjuvants like CFA/IFA or isoprenoids like pristane.
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